Novel indole or benzimidazole derivatives

FIELD: chemistry.

SUBSTANCE: present invention relates to compounds of formula I , where X is N or CH; R1 is -C(O)-NR8R9 or -C(O)-OR10, and R2 is hydrogen; or alternatively R2 is and R1 is hydrogen or halogen; Y is N or CH; R3, R4, R5 and R6 are independently selected from a group consisting of hydrogen, halogen, (lower)alkoxy, (lower)fluoroalkyl, (lower)fluoroalkoxy and (lower)fluoroalkylsulfanyl; or R3 and R4 together with carbon atoms with which they are bonded form a 6-member unsaturated ring which can contain one nitrogen heteroatom; R7 is hydrogen or (lower)alkyl; R8 is hydrogen or NH2; R9 is selected from a group consisting of (lower)alkyl, (lower)alkenyl, (lower)alkoxyalkyl, -(CH2)m-(C3-C7)cycloalkyl, -(CH2)m-piperidinyl, -(CH2)m-phenyl, where the phenyl ring is unsubstituted or substituted with one or two groups selected from halogen, (lower)alkoxy, (lower)fluoroalkyl and (lower)fluoroalkoxy, -(CH2)m-naphthyl and pyridylamino; R10 is (lower)alkenyl; R11 is selected from a group consisting of -C(O)-R12, -SO2-R13 and -SO2-NR14R15; R12 is selected from a group consisting of (lower)alkyl, (lower)alkoxyalkyl, -(CH2)n-(C3-C7)-cycloalkyl, -(CH2)n-phenyl and -(CH2)n-pyridyl, where phenyl or pyridyl are unsubstituted or substituted with one (lower)alkyl; R13 is selected from (lower)alkyl or -(CH2)n-phenyl, where phenyl is unsubstituted or substituted with one (lower)alkyl; R14 is (lower)alkyl; R15 is (lower)alkyl; m equals 0, 1 or 2; n equals 0 or 1; and all their pharmaceutically acceptable salts. The invention also relates to a pharmaceutical composition based on formula I compounds.

EFFECT: novel indole and benzimidazole derivatives which have modulating effect on the CB1 receptor are obtained.

26 cl, 3 tbl, 148 ex

 

The text descriptions are given in facsimile form.

1. Compounds of General formula

where X is N or CH;
R1means-C(O)-NR8 R9or-C(O)-OR10and
R2means hydrogen; or
alternative
R2means
and
R1means hydrogen or halogen;
Y represents N or CH;
R3, R4, R5and R6chosen independently of one another from the group consisting of hydrogen, halogen, (ness.)alkoxy, (ness.)foralkyl, (ness.)feralcode and (ness.)peralkaline; or
R3and R4form together with the carbon atoms to which they are attached, form a 6-membered unsaturated ring which may contain one nitrogen heteroatom;
R7means hydrogen or (ness.)alkyl;
R8means hydrogen or NH2;
R9selected from the group consisting of (ness.)of alkyl, (ness.)alkenyl, (ness.)alkoxyalkyl, -(CH2)m-(C3-C7)cycloalkyl, -(CH2)m-piperidinyl, -(CH2)m-phenyl, where the phenyl ring is unsubstituted or substituted by one or two groups selected from halogen, (ness.)alkoxy, (ness.)foralkyl and (ness.)feralcode, -(CH2)m-naphthyl, pyridylamino;
R10means (ness.)alkenyl;
R11selected from the group consisting of-C(O)-R12, -SO2-R13and-SO2-NR14R15;
R12selected from the group consisting of (ness.)of alkyl, (ness.)alkoxyalkyl, -(CH2)n-C 3-C7)-cycloalkyl, -(CH2)n-phenyl and -(CH2)n-pyridyl, where the phenyl or pyridyl are unsubstituted or substituted by one (ness.)by alkyl;
R13choose from (ness.)the alkyl or -(CH2)n-phenyl, where phenyl is unsubstituted or substituted by one (ness.)by alkyl;
R14means (ness.)alkyl;
R15means (ness.)alkyl;
m means 0, 1 or 2;
n means 0 or 1; and
all their pharmaceutically acceptable salts.

2. The compounds of formula I according to claim 1, where X means nitrogen.

3. The compounds of formula I according to claim 1, where
R1means-C(O)-NR8R9or-C(O)-OR10,
R2means hydrogen, and
R8, R9and R10have such values that are defined according to claim 1.

4. The compounds of formula I according to claim 1, where
R1means-C(O)-NR8R9,
R2means hydrogen, and
R8and R9have such values that are defined according to claim 1.

5. The compounds of formula I according to claim 4, where
R8means hydrogen, and
R9selected from the group consisting of (ness.)of alkyl, (ness.)alkenyl, (ness.)alkoxyalkyl, -(CH2)m-(C3-C7)cycloalkyl, -(CH2)m-piperidinyl, -(CH2)m-phenyl, where the phenyl ring is unsubstituted or substituted by one or two groups selected from halogen, (ness.)alkoxy, (ness.)foralkyl and (not the sh.)feralcode, -(CH2)m-naphthyl, pyridylamino, and
m means 0, 1 or 2.

6. The compounds of formula I according to claim 4, where
R9selected from the group consisting of (ness.)of alkyl, -(CH2)m-(C3-C7)cycloalkyl and -(CH2)m-piperidinyl.

7. The compounds of formula I according to claim 1,
where R2means

R1means hydrogen or halogen, and
R11has the meaning given in claim 1.

8. The compounds of formula I according to claim 7, where
R11means-C(O)-R12and
R12has the meaning given in claim 1.

9. The compounds of formula I of claim 8, where
R12means (ness.)alkyl or -(CH2)n-phenyl, where phenyl is unsubstituted or substituted (ness.)the alkyl.

10. The compounds of formula I according to claim 7, where
R11means-SO2-R13and
R13has the meaning given in claim 1.

11. The compounds of formula I of claim 10, where
R13means (ness.)alkyl.

12. The compounds of formula I according to claim 7, where
R11means-SO2-NR14R15and
R14and R15mean (ness.)alkyl.

13. The compounds of formula I according to claim 1, where X denotes CH.

14. The compounds of formula I according to item 13, where
R1means-C(O)-NR8R9,
R2means hydrogen, and
R8and R9have such values that are defined according to claim 1.

15. The compounds of formula I through 14, where
R 8means hydrogen, and
R9selected from the group consisting of (ness.)of alkyl, -(CH2)m-(C3-C7)cycloalkyl and -(CH2)m-piperidinyl, and
m means 0, 1 or 2.

16. The compounds of formula I according to claim 1, where Y represents CH.

17. The compounds of formula I according to claim 1, where at least one of R3, R4, R5and R6selected from the group consisting of halogen, (ness.)alkoxy, (ness.)foralkyl, (ness.)feralcode and (ness.)peralkaline;
or R3and R4together with the carbon atoms to which they are attached, a 6-membered unsaturated ring which may contain one heteroatom of nitrogen.

18. The compounds of formula I according to claim 1, where
R5selected from the group consisting of halogen, (ness.)alkoxy, (ness.)foralkyl, (ness.)feralcode and (ness.)peralkaline, and
R3, R4and R6mean hydrogen.

19. The compounds of formula I according to claim 1, where
R3selected from the group consisting of halogen, (ness.)alkoxy, (ness.)foralkyl, (ness.)feralcode and (ness.)peralkaline, and
R4, R5and R6mean hydrogen.

20. The compounds of formula I according to claim 1, where
R4selected from the group consisting of halogen, (ness.)alkoxy, (ness.)foralkyl, (ness.)feralcode and (ness.)peralkaline, and
R3, R5and R6mean hydrogen.

21. Connection f is rmula I according to claim 1, where R7means hydrogen or methyl.

22. The compounds of formula I according to claim 1, selected from the group consisting of:
6-[4-(butane-1-sulfonyl)piperazine-1-yl]-2-phenoxymethyl-1-(4-triptoreline-benzyl)-1H-benzoimidazole,
dimethylamide 4-[2-phenoxymethyl-3-(4-cryptomaterial)-3H-benzoimidazol-5-yl]piperazine-1-sulfonic acid,
dimethylamide 4-[2-(1-phenoxyethyl)-3-(4-cryptomaterial)-3H-benzoimidazol-5-yl]piperazine-1-sulfonic acid,
{4-[2-(1-phenoxyethyl)-3-(4-trifloromethyl)-3H-benzoimidazol-5-yl]-piperazine-1-yl}-o-tailltean,
dimethylamide 4-[3-(4-Chlorobenzyl)-2-(1-phenoxyethyl)-3H-benzoimidazol-5-yl]-piperazine-1-sulfonic acid,
{4-[3-(4-[Chlorobenzyl)-2-(1-phenoxyethyl)-3H-benzoimidazol-5-yl]piperazine-1-yl}phenylmethanone,
butylamide 2-phenoxymethyl-1-(4-cryptomaterial)-1H-benzoimidazol-5-carboxylic acid,
cyclopropylamine 2-phenoxymethyl-1-(4-cryptomaterial)-1H-benzoimidazol-5-carboxylic acid,
{4-[6-fluoro-2-phenoxymethyl-3-(4-cryptomaterial)-3H-benzoimidazol-5-yl]piperazine-1-yl}phenylmethanone,
1-{4-[3-(4-Chlorobenzyl)-6-fluoro-2-phenoxymethyl-3H-benzoimidazol-5-yl]-piperazine-1-yl}pentane-1-it,
1-{4-[6-fluoro-2-phenoxymethyl-3-(4-cryptomaterial)-3H-benzoimidazol-5-yl]piperazine-1-yl}butane-1-it, and
all their pharmaceutically acceptable salts.

23. The compounds of formula I according to claim 1, selected from the group consisting of the C:
butylamide 2-phenoxymethyl-1-(4-triftormetilfullerenov)-1H-indole-5-carboxylic acid,
cyclopropylamine 1-(2-chloro-5-trifloromethyl)-2-phenoxymethyl-1H-indole-5-carboxylic acid,
butylamide 2-phenoxymethyl-1-(4-cryptomaterial)-1H-indole-5-carboxylic acid,
butylamide 1-(4-methoxybenzyl)-2-phenoxymethyl-1H-indole-5-carboxylic acid,
piperidine-1-ylamide 2-phenoxymethyl-1-(2-cryptomaterial)-1H-indole-5-carboxylic acid,
butylamide 2-phenoxymethyl-1-(3-triftormetilfullerenov)-1H-indole-5-carboxylic acid,
cyclopropylamine 2-phenoxymethyl-1-(2-cryptomaterial)-1H-indole-5-carboxylic acid,
cyclopropylamine 2-phenoxymethyl-1-(4-triftormetilfullerenov)-1H-indole-5-carboxylic acid,
cyclopropylamine 2-phenoxymethyl-1-(4-cryptomaterial)-1H-indole-5-carboxylic acid,
butylamide 2-phenoxymethyl-1-(2-cryptomaterial)-1H-indole-5-carboxylic acid and
all their pharmaceutically acceptable salts.

24. Pharmaceutical composition having modulating activity against receptor SV1comprising the compound according to any one of claims 1 to 23 and a pharmaceutically acceptable carrier and/or excipient.

25. Compounds according to claim 1, having a modulating action on the receptor SV1.

26. Compounds according to claim 1 for use as therapeuti the Eski active substances for the treatment and/or prevention of diseases, which is associated with modulation of receptor SV1.



 

Same patents:

FIELD: chemistry.

SUBSTANCE: invention refers to compounds of the formula (I) and pharmaceutically acceptable salts, where R1-R7 mean the same as provided in the invention description and claim. Compounds of the formula (I) are specific inhibitors of 11b-HSD1. They can be applied in treatment and/or prevention of diseases caused by dysfunctions related to 11b-HSD1 enzyme, particularly in treatment and/or prevention of metabolic diseases, obesity, dyslipidemia, hypertension and/or diabetes, especially diabetes type "П". Additionally subject matter includes pharmaceutical composition for treatment and/or prevention of the said diseases.

EFFECT: improved efficiency of derivatives.

21 cl, 1 tbl, 146 ex

FIELD: chemistry.

SUBSTANCE: invention refers to compounds of the formula (I): , where R1 is C1-C8alkyl optionally substituted with one to three substitutes selected out of substitute group A; R2 is C1-C6alkyl or C1-C6alkoxyC1-C6alkyl; R3 is C1-C6alkyl or C1-C6alkoxy; or R2 and R3 together with adjoining carbon atoms form optionally substituted non-aromatic 5-10-member carbon ring; R4 is hydrogen; G is group represented by the formula: or the rest as provided in the invention claim; and to pharmaceutical composition, application of claimed compounds, and method of atopic dermatitis prevention or treatment.

EFFECT: novel compounds useful as atopic dermatitis treatment medication and antipruritic medicines.

24 cl, 75 ex, 290 tbl

FIELD: chemistry.

SUBSTANCE: agent is a 6-bromo-5-methoxy-indole-3-carboxylic acid derivative of general formula (I) , where B is a N(R)2 group, where both R groups together with the nitrogen atom to which they are bonded form a 5-6-member heterocyclic ring containing 1-2 heteroatoms selected from nitrogen, such as pyrrolidine, piperidine, piperazine or morpholine, where each of the said heterocyclic rings can be substituted with C1-4alkyl, phenyl, benzyl, phenethyl, carbonylamino, -COOC1-4alkyl group or -COOC1-4alkyl group and phenyl, which can also be substituted or have substitutes selected from halogen, C1-4alkyl, C1-4alkoxy, and alkyl in the said groups can be linear or branched; R1 is C1-4alkyl, phenyl, possibly substituted with C1-4alkyl or C1-4alkoxy, halogen atoms; R2 is -S-phenyl, -S-benzyl, -O-phenyl, where in each of the said groups, the phenyl ring is possibly substituted with C1-4alkyl, C1-4alkoxy, halogen atoms, or R2 denotes a -N(R)2 group, or pharmaceutically acceptable salts thereof.

EFFECT: agent has antiviral activity towards influenza A virus.

3 dwg, 2 tbl, 8 ex

FIELD: chemistry.

SUBSTANCE: invention relates to novel compounds having general formula (I) given below, , where R1 represents a hydrogen atom, C1-C6 alkyl group, C3-C6 cycloalkyl group or C1-C6 alkoxy group; R2 is a hydrogen atom or C1-C6 alkyl group; R3 is a substituted C1-C6 alkyl group {said substitute is a heterocyclyl group or heterocyclyl group substituted with 1-5 substitutes selected from <a group of substitutes α> (said heterocyclyl groups can be substituted with 1-4 oxo groups); a heteroaryl group or a heteroaryl group substituted with 1-5 substitutes selected from <a group of substitutes α>; or a substitute selected from <a group of substitutes β>}, or a heterocyclyl group or a heterocyclyl group substituted with 1-5 substitutes selected from <a group of substitutes α> (said heterocyclyl groups can be substituted with 1-4 oxo groups); where the heteroaryl group is a 5- or 6-member aromatic heterocyclic group containing at least one nitrogen atom, and the heterocyclyl group is a partially or completely reduced 5- or 6-member heterocyclic group containing 1-3 sulphur atoms, oxygen atoms and/or nitrogen atoms; X1, X2, X3, X4 and X5 each independently represents a hydrogen atom or a halogen atom; n equals 1, < group of substitutes α> is a carboxy group, C2-C7 alkoxycarbonyl group, carbamoyl group, hydroxyl group, C1-C6 alkyl group, C2-C7 alkanoyl group, C2-C7 alkylcarbamoyl group, di(C1-C6 alkyl)carbamoyl group or a group of formula R4-CO-CR5R6-(CH2)m-, where R4 represents a hydroxyl group or a C1-C6 alkoxy group; R5 and R6 are identical or different and each represents a hydrogen atom or a C1-C6 alkyl group; and m equals an integer ranging from 0 to 5; and <group of substitutes β> is represents a carboxy group, C2-C7alkoxycarbonyl group, carbamoyl group, cyano group, hydroxyl group, C1-C6 alkoxy group, C2-C7 alkylcarbamoyl group, di(C1-C6 alkyl)carbamoyl group and a group of formula R9-CO-(CH2)k-N(R10)- {where R9 represents a hydroxyl group or C1-C6 alkoxy group; R10 represents a hydrogen atom or C1-C6 alkyl group; and k equals an integer from 0 to 5}, to pharmacologically acceptable salts thereof and to C1-C6 alkanoyl derivatives. The invention also relates to a pharmaceutical composition, to use as well as to a method of preventing or therapy for diseases related to thrombosis or embolus formation.

EFFECT: obtaining novel biologically active compounds having inhibitory activity towards thrombocyte aggregation.

24 cl, 118 ex, 8 tbl

FIELD: chemistry.

SUBSTANCE: proposed invention relates to a method of producing symmetrical gem-diamines with general formula where , involving reacting secondary acyclic or cyclic amines R2NH with excess N,N,N1,N1-tetramethyl methanediamine in the presence of a copper chloride (CuCl) catalyst at temperature 80°C and atmospheric pressure for 2-4 hours. Output of symmetrical gem-diamines is 85-98%.

EFFECT: improved method.

2 dwg, 7 ex

FIELD: chemistry.

SUBSTANCE: invention proposes 5-member heterocyclic inhibitors of kinase p38, including kinase p38α and kinase p38β, based on pyrazoles and imidazoles, with the general formula given below , in which ring B is phenyl, and C is a pyrazole or imidazole ring, and the rest of the symbols assume values given in paragraph 1 of the formula of invention.

EFFECT: there are described pharmaceutical compositions containing said compounds, as well as methods of using the compounds and compositions, including a method of treating, preventing or suppressing one or more symptoms of diseases and conditions mediated by kinase p38 which include, but not limited to, inflammatory diseases and conditions.

31 cl, 6 tbl, 175 ex

FIELD: chemistry.

SUBSTANCE: invention relates to a novel compound N-(1-{(3R)-3-(3,5-difluorophenyl)-3-[1-(methylsulfonyl) piperidin-4-yl]propyl}piperidin-4-yl)-N-ethyl-2-[4- (methylsufonyl)phenyl]acetamide or its pharmaceutically acceptable salts. The invention also relates to a method for synthesis of the compound in paragraph 1, as well as to a pharmaceutical composition.

EFFECT: obtaining a novel biologically active compound with activity towards CCR5 (chemokine receptor 5).

6 cl, 6 ex, 2 tbl

FIELD: chemistry.

SUBSTANCE: present invention relates to novel derivatives of aminobenzimidazole and benzimidazole of general formula (I-b-1), additive salt or stereochemically isomeric form thereof, where G is a single bond or C1-10alkanediyl; R1 is halogenphenyl, pyridyl, pyrazinyl, quinolinyl, benzimidazoly or a radical of formula (c-4), where each of the said monocyclic or bicyclic heterorings can be optionally substituted with 1, 2 or 3 substitutes, independently selected from a group consisting of halogen, hydroxy, C1-6alkyl, C1-6alkyloxy, Ar1C1-6alkyloxy, C1-6alkyloxy-CH2-CH2-O-; m equals 2; Q is hydrogen, amino or mono(C1-4alkyl)amino; R3b is hydrogen or C1-6alkyl; R4a is selected from a group of substitutes consisting of hydrogen, Ar2C1-6alkyl, Het- C1-6alkyl, hydroxy C1-6alkyl, (hydroxyC1-6alkyl)oxy C1-6alkyl, C1-6alkyl, (Ar1C1-6alkyloxy)(hydroxy)C1-6alkyl, aminoC1-6alkyl, mono- and di(C1-6alkyl)amino-C1-6alkyl, carboxyl-C1-6alkyl, C1-6alkyloxycarbonyl C1-6alkyl, aminocarbonylC1-6alkyl, (C1-4alkyloxy)2-P(=O)-C1-6alkyl, aminosulphonylC1-6alkyl; R6a is hydrogen or C1-6alkyl; R6b is hydrogen, C1-6alkyl, Ar1 or Ar1C1-6alkyl; R6c is C1-6alkyl; Alk is C1-6alkanediyl; R9, R10, R11 are each independently selected from halogen, cyano, C1-6alkyl, Het-C1-6alkyl, Ar1C1-6alkyl, cyano C1-6alkyl, C2-6alkenyl, R6b-O-C3-6alkenyl, C2-6alkynyl, Ar1, R6b-O-, R6b-S-, R6b-O- C1-6alkyl-SO2-, polyhalo-C1-6alkyl, polyhaloC1-6alkyloxy, polyhaloC1-6alkylthio, R6c-C(=O)-, R6b-O-C(=O)-, N(R6aR6b)-C(=O)-, R6b-O-C1-6alkyl, R6b-O-C(=O)-C1-6alkyl, N(R6aR6b)-C(=O)-C1-6alkyl, R6c-C(=O)-NR6b-, N(R6aR6b)-S(=O)2-, H2N-C(=NH)-, and R10 and/or R11 can also be hydrogen; Ar1 is phenyl; Ar2 is phenyl; Het is a heteroring selected from imidazolyl or morpholinyl. The invention also relates to a pharmaceutical composition based on formula (I-b-1) compound, use of formula (I-b-1) compound to prepare a medicinal agent and a method of producing formula (I-b-1) compound.

EFFECT: novel aminobenzimidazole and benzimidazole derivatives with antiviral activity are obtained.

15 cl, 8 tbl, 31 ex

FIELD: chemistry.

SUBSTANCE: invention relates to organic chemistry, and specifically to (2R)-2-{(1S)-6,7-dimethoxy-1-[2-(4-trifluoromethylphenyl)-ethyl]-3,4-dihydro-1H-isoquinolin-2-yl}-N-methyl-2-phenylacetamide or pharmaceutically acceptable salt thereof. The invention also relates to use and a pharmaceutical composition based on said compound with non-peptide antagonistic activity of human orexin receptors.

EFFECT: obtaining a novel compound and its salt, which can be used in medicine as a medicinal agent for preventing or treating diseases such as nutritional and sleep disorders.

11 cl, 3 tbl, 4 ex

FIELD: medicine.

SUBSTANCE: invention is related to new derivatives of aryl and heteroarylpiperidinecarboxylates, of formula (I): , where: type means integer numbers from 1 to 3, such that m+n is integer number from 2 to 5; p means integer number from 1 to 7; A means simple connection or is selected from one or several groups X, Y; X means -CH2-; Y means C2-alkynilene group; R1 means group R5, substituted with one or several groups R6 and/or R7; R2 means H, F, OH; R3 means H; R4 means H, C1-6-alkyl; R5 means group selected from phenyl, pyridinyl, pyrimidinyl, pyrrolyl, imidazolyl, thiazolyl, pyrazolyl, isoxazolyl, oxadiazolyl, naphthyl, chinolynyl, tetrahydrochinolinyl, isochinolinyl, tetrahydroisochinolinyl, indolyl, indolinyl, isoindolyl, benzimidazolyl, benzoxazolyl, benzizoxazolyl, benzothiazolyl, benzithiazolyl, benzotriazolyl, benzoxadiazolyl, pyrrolopyridinyl; R6 means halogen, CN, C1-6-alkyl, C3-7-cycloalkyl, C1-6-alkoxy, OH, C1-6-fluoroalkyl, C1-6-fluoroalkoxy, or cycle selected from pyrrolidine and piperidine cycle, besides this cycle is unnecessarily substituted with C1-6-alkyl group; R7 means phenyl group, besides group or groups R7 may be substituted with one or several groups R6, identical or differing from each other, selected from halogen, C1-6-alkyl and C1-6-fluoroalkyl, C1-6-alkoxy, in the form of pharmaceutically acceptable base or acid-additive salt.

EFFECT: compounds are applicable as inhibitors of FAAH ferment.

10 cl, 1 tbl, 7 ex

FIELD: chemistry.

SUBSTANCE: invention relates to new benzimidazole derivatives with general formula (I), where A represents -CH2-, -C(O), -C(O)-C(Ra)(Rb)-, X represents a -CH- radical; Ra and Rb independently represent a hydrogen atom or (C1-C6)alkyl radical; R1 represents a hydrogen atom or (C1-C8)alkyl radical; R2 represents a (C1-C8)alkyl radical; R3 represents -(CH2)P-Z3, -C(O)-Z'3 or -C(O)-NH-Z"3; Z3 represents (C1-C6)alkyl, (C2-C6)alkenyl, (C1-C6)alkoxy, (C1-C6)alkylcarbonyl, (C1-C6)alkoxycarbonyl, (C1-C6)alkyl-N(RN)carbonyl, (C3-C7)cycloalkyl, aryl, arylthio or heteroaryl radical, Z3 is bonded to the -(CH2)P- through a carbon atom, heteroaryl radical, which is a 5-10- member heteroaryl, which contains 1-2 identical or different heteroatoms, chosen from sulphur, nitrogen or oxygen, and optionally substituted with one or more identical or different substitutes, chosen from halogen, nitro group or -(CH2)P'-V30-Y3; aryl radical, chosen from phenyl or naphthyl, optionally substituted with one or more identical or different substitutes, chosen from halogen, nitro group, cyano group, (C2-C6)alkenyl, pyrrolidinyl, phenyl, phenyloxy, phenylalkyloxy, 5-7- member heteroaryl, containing 1-3 nitrogen atoms and -(CH2)p'-V31-Y3; V30 represents -O-, -C(O)-, -C(O)-O- or a covalent bond; V31 represents -O-, -S-, -SO2-, -C(O)-, -C(O)-O-, -N(RN)-, -NH-C(O)- or a covalent bond; Y3 represents a hydrogen atom or (C1-C6)alkyl radical, optionally substituted with one or more identical or different halogen radicals; RN represents a hydrogen atom or (C1-C6)alkyl radical; Z3 represents a radical with a given formula (see below); Z'3 represents a phenyl radical, optionally substituted with one ore more identical or different substitutes, chosen from -(CH2)P"-V'3-Y'3; V'3 represents -O-; Y'3 represents a hydrogen atom or (C1-C6)alkyl radical; Z"3 represents a hydrogen atom or -(CH2)q-A"3 radical; A"3 represents (C1-C6)alkyl, phenyl or thienyl radical; alkyl or phenyl radical can be optionally substituted with one or more identical or different substitutes, chosen from halogen and -V"3-Y"3; V"3 represents -O-, -C(O)-, -C(O)-O- or a covalent bond; Y"3 represents a hydrogen atom or (C1-C6)alkyl radical; p is an integer from 0 to 6; p' and p" independently represent an integer from 0 to 1; q is an integer from 0 to 2; R4 represents a radical with formula -(CH2)S-R'4; R'4 represents a 5-7- member heterocycloalkyl, containing at least one nitrogen atom and optionally substituted with (C1-C6)alkyl; or a radical with formula -NW4W'4; W4 represents a hydrogen atom; W'4 represents a hydrogen atom; s is an integer from 0 to 6; in racemic or enantiomeric form or any combination of the said forms, or its pharmaceutically acceptable salt. The invention also relates to a method of obtaining a compound in paragraph 1, a pharmaceutical composition based on the said compound and its use in making a medicinal agent.

EFFECT: new benzimidazole derivatives have good affinity to certain subtypes of melanocortin receptors.

26 cl, 8 ex

FIELD: chemistry.

SUBSTANCE: description is given of a derivative of propane-1,3-dione with general formula (I) and its pharmaceutical salt, in which symbols denote the following: ring A: benzol, which can be substituted, pyridine, which can be substituted or a thiophene ring; ring B: benzene or thiophene ring; R1: H or -CO-inferior alkyl; R2: H, -O-R5, -N(R6)R7, -N3, -S(O)m-inferior alkyl, pyridyl or imidazole, which can be substituted; R3: H or inferior alkyl; X: a bond, inferior alkylene, which can be substituted, or cycloalkanediyl. Description is also given of propane-1,3-dione derivatives with formulae (Ia) and (Ib) and a pharmaceutical composition. The proposed compounds are useful as GnRH receptor antagonists, can be used in curing diseases, which depend on sex hormones, such as prostate cancer, breast cancer, endometriosis, uterine leiomyoma and non-malignant hypertrophy of the prostate gland.

EFFECT: obtaining compounds, useful for curing diseases, which depend on sex hormones, such as prostate cancer, breast cancer, endometriosis, uterine leiomyoma and non-malignant hypertrophy of the prostate gland.

10 cl, 26 tbl, 23 ex

FIELD: organic chemistry, medicine, pharmacy.

SUBSTANCE: invention relates to therapeutic agents showing effectiveness in treatment of pain, cancer, cerebrospinal sclerosis, Parkinson's disease, Huntington's chorea and/or Alzheimer's disease. Invention describes compound of the formula (I): or its pharmaceutically acceptable salts wherein RF1 and RF2 represent independently electron-acceptor groups; Z is chosen from O=; R1 is chosen from (C1-C10)-alkyl, heterocyclyl-(C1-C6)-alkyl, substituted heterocyclyl-(C1-C6)-alkyl; R2 is chosen from (C1-C6)-alkyl; X represents bivalent (C1-C10)-group that separates groups added to it by one or two atoms; Ar represents bivalent (C4-C12)-aromatic group, and Y is chosen from =CH=. Also, invention describes fields wherein compounds of the formula (I) are used, a pharmaceutical composition based on thereof, and methods for their synthesis. Invention provides synthesis of novel compounds possessing useful biological properties.

EFFECT: valuable medicinal properties of compounds and pharmaceutical composition.

17 cl, 2 tbl, 35 ex

FIELD: organic chemistry, medicine, pharmacy.

SUBSTANCE: invention relates to novel compounds of the formula (I): or its pharmaceutically acceptable salts that possess properties of CB2 receptors agonist and can be used in preparing drugs exerting analgesic effect, in particular, for pain treatment. In compound of the formula (I) R1 is chosen from group consisting of (C1-C6)-alkyl, (C3-C6)-cycloalkyl, (C3-C6)-cycloalkyl-(C1-C6)-alkyl, (C2-C6)-alkenyl, R42N-(C1-C6)-alkyl, R42NC(=O)-(C1-C6)-alkyl, R4O-(C1-C6)-alkyl, R4OC(=O)-(C1-C6)-alkyl, R4C(=O)-(C1-C6)-alkyl, R4C(=O)-NR4-(C1-C6)-alkyl, R42NSO2-(C1-C6)-alkyl, R42NC(=O)-NR4-(C1-C6)-alkyl, radicals phenyl-(C1-C6)-alkyl, heteroaryl-(C1-C6)-alkyl, heterocycloalkyl-(C1-C6)-alkyl, bicyclic heteroaryl-(C1-C6)-alkyl; Ar represents phenyl or pyridyl; R2 represents (C1-C6)-alkyl that is unsubstituted or substituted at 1-6 carbon atoms with one or more fluorine atom substitute or (C3-C6)-cycloalkyl; R3 is chosen from the following group consisting of: (a) , (b) , (c) , (d) , (e) , (f) , (g) , (h) , (i) , (j) and (k) ; R4 represents group chosen independently from group consisting of hydrogen atom (H), (C1-C6)-alkyl, (C2-C6)-alkenyl; groups R5 are chosen independently from group consisting of H, (C2-C6)-alkenyl; groups R6 are chosen independently from group consisting of H, (C1-C6)-alkyl, (C3-C6)-cycloalkyl, (C2-C6)-alkenyl, heterocyclyl, radical (C1-C3)-alkyl, phenyl, radical phenyl-(C1-C3)-alkyl, heteroaryl, radicals heteroaryl-(C1-C3)-alkyl, bicyclic heteroaryl and bicyclic heteroaryl-(C1-C3)-alkyl; R5 and R6 can be combined to form 5-7-membered heterocycle; X is chosen from group consisting of -C(R5)2-, -NR5-, C(=O)-, -CH2-CH2-, CH=CH- and -C(R)(R') wherein R and R' represent (C1-C6)-alkyl, -OR'' or H and R'' represents H; Y represents -CH or nitrogen atom and wherein heterocyclyl or heterocycloalkyl represent 5-6-membered ring comprising from 1 to 2 heteroatoms chosen from nitrogen (N) and oxygen (O) atoms that is unsubstituted or substituted with (C1-C6)-alkyl; heteroaryl represents heteroaromatic 5-6-membered ring comprising from 1 to 2 heteroatoms chosen from N, S and sulfur atom (S) that is unsubstituted or substituted with group chosen from group consisting of (C1-C6)-alkyl, nitro-group, halogen atom and acetoxymethyl; bicyclic heteroaryl represents 5-6-membered nitrogen-containing ring condensed with benzene ring. Also, invention relates to a pharmaceutical composition and a method for paintreatment.

EFFECT: valuable medicinal properties of compounds and pharmaceutical composition.

9 cl, 15 sch, 3 tbl, 130 ex

-substituted derivatives of carboxylic acids" target="_blank">

The invention relates tosubstituted derivatives of carboxylic acids, characterized by the General formula (I), (II), (III) and (IV)

< / BR>
< / BR>
< / BR>
< / BR>
or their pharmacologically acceptable (C1-C6)-alkyl esters, or their pharmacologically acceptable Amida, or their pharmacologically acceptable salts

FIELD: chemistry; pharmaceutics.

SUBSTANCE: present invention relates to novel cyclohexane derivatives of formula (I) or their pharmaceutically acceptable salts having inhibitory effect on Na+-glucose cotranspoter (SGLT2), as well as to pharmaceutical compositions based on the said compounds and their use in preventing or treating diabetes, diabetic complications caused by hyperglycaemia or obesity. , where A is -O-; n is an equal to 0 or 1; R6 and R7 each independently represents a hydrogen atom or a C1-C6alkyl group, m is an integer selected from 1-3; Q is selected from Q1 - Q5, given in formula 2.

EFFECT: obtaining novel cyclohexane derivatives or their pharmaceutically acceptable salts and preparation of a pharmaceutical composition based on the said compounds.

15 cl, 19 dwg, 11 tbl, 86 ex

FIELD: chemistry.

SUBSTANCE: novel compound is N-(5-hydroxy-2,4-di-tert-butylphenyl)-4-oxo-1H-quinoline-3-carboxamide or its pharmaceutically acceptable salts. The invention also relates to a pharmaceutical composition.

EFFECT: obtaining a novel biologically active compound with CFTR activity modulation properties.

2 cl, 485 ex, 3 tbl

FIELD: chemistry.

SUBSTANCE: invention relates to synthesis of new complexing analytical reagents which are suitable for doping nanoparticles and for use in luminescence-spectral analysis, biochip technology, as well as extractants of ions of heavy and rare-earth metals. Description is given of complexing benzo-containing heterocyclic compounds, which contain a β-dicarbonyl substitute with fluorinated radicals of formula: HetAr-C(O)CH2C(O)CF3, where HetAr= ,

which form luminescent complexes with Eu3+ ions. Proposed compounds are on the same level as compounds with closely resembling structure with regards to duration of luminescence and bonding efficiency, although they are easily accessible with respect technology of production and have high water solubility >10-4 mol/l, which enables their use in making conceptually new biochips with time, spatial and spectral signal selection.

EFFECT: high output of desired product.

1 cl, 5 dwg, 1 tbl, 6 ex

FIELD: chemistry.

SUBSTANCE: invention relates to formula (I) compounds and to their use in treating diseases related to lipid storage disorders, such as atherosclerosis and diabetes. In R1 represents hydrogen, alkyl, halogen, formyl, hydroxyalkyl or trifluoromethyl, R2 represents hydrogen, alkyl or halogen, R3 represents hydrogen or alkyl, R4 represents hydrogen, alkyl, hydroxy or alkoxy, R5 and R6 are chosen from hydrogen, alkyl, phenylalkyl, hydroxyalkyl, alkoxycarbonyl and phenyl, A represents aryl or heterocyclyl, m equals 0-3, n equals 0-1, p equals 0-3, sum of m, n and p equals 1-4, the bond between carbon atoms Ca and Cb is a single or double carbon-carbon bond.

EFFECT: obtaining new biologically active compounds.

27 cl, 147 ex

Up!